About aridis pharmaceuticals inc - ARDS
Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using human monoclonal antibodies, or mAbs, to treat infections. The company was founded by Eric J. Patzer and Vu L. Truong on April 24, 2003 and is headquartered in Los Gatos, CA.
ARDS At a Glance
Aridis Pharmaceuticals, Inc.
983 University Avenue
Los Gatos, California 95032
| Phone | 1-408-385-1742 | Revenue | 3.09M | |
| Industry | Pharmaceuticals: Major | Net Income | -30,371,000.00 | |
| Sector | Health Technology | 2022 Sales Growth | 101.368% | |
| Fiscal Year-end | 12 / 2023 | Employees | 37 | |
| View SEC Filings |
ARDS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 7.168 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.787 |
| Enterprise Value to Sales | 7.515 |
| Total Debt to Enterprise Value | 0.264 |
ARDS Efficiency
| Revenue/Employee | 83,540.541 |
| Income Per Employee | -820,837.838 |
| Receivables Turnover | 2.493 |
| Total Asset Turnover | 0.149 |
ARDS Liquidity
| Current Ratio | 0.261 |
| Quick Ratio | 0.261 |
| Cash Ratio | 0.137 |
ARDS Profitability
| Gross Margin | 84.245 |
| Operating Margin | -970.333 |
| Pretax Margin | -982.562 |
| Net Margin | -982.562 |
| Return on Assets | -146.398 |
| Return on Equity | N/A |
| Return on Total Capital | 167.777 |
| Return on Invested Capital | N/A |
ARDS Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -33.864 |
| Total Debt to Total Assets | 41.715 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | -7.137 |